Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Identifies Hidden Heart Valve Defects from Patient’s ECG

By HospiMedica International staff writers
Posted on 08 Aug 2025

Heart valve diseases, affecting over 41 million people globally, can lead to heart failure, hospitalization, and even death. More...

Early diagnosis is critical, yet symptoms like shortness of breath or dizziness are often misattributed, and some patients show no signs until the disease is advanced. Subtle changes in heart function, especially in its electrical activity, often go undetected until it’s too late. Researchers have now created an artificial intelligence (AI) tool to identify risk much earlier, using just a standard electrocardiogram (ECG).

Developed by researchers at Imperial College London (London, UK), the AI model uses a patient’s ECG to predict the risk of developing regurgitant valvular heart diseases. These conditions, which affect the mitral, tricuspid, or aortic valves, involve blood leaking backwards through the heart. The AI detects early structural changes in the heart that are not apparent to doctors, making it possible to flag high-risk patients earlier than ever before physical symptoms or damage appear.

The research team trained the algorithm on nearly one million ECG and echocardiogram records from over 400,000 patients in China. To ensure accuracy across populations, the tool was then validated on over 34,000 patients in the US, showing that it works well across ethnically diverse populations and healthcare systems. The study, published in The European Heart Journal, shows that the AI model successfully predicted valve disease risk 69–79% of the time, showing reliable performance across diverse ethnic groups and healthcare settings.

Additionally, high-risk patients identified by the AI were up to 10 times more likely to develop valve leakage, offering a critical window for prevention. This technology could revolutionize care by identifying patients in need of monitoring or early intervention, long before heart valve disease causes harm. The research follows on from the team’s development of the related AI-ECG risk estimation model, known as AIRE, which can predict patients’ risk of developing and worsening disease from an ECG.

“Our work is harnessing AI to detect subtle changes at the earliest stage from a simple and common test, and we think this could be really transformative for doctors and patients,” said Dr. Arunashis Sau, one of the study leads. "Rather than waiting for symptoms or relying only on expensive and time-consuming imaging tests, we could use AI-enhanced ECGs to spot those most at risk earlier than ever before."


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.